Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.67 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512125 | 0.91 | POLB (0.72) | POLBALDH1A1TP53BP1MRGPRX4TP53 | |
| SCHEMBL3514277 | 0.88 | POLB (0.76) | POLBALDH1A1TP53BP1TP53NAMPT | |
| SCHEMBL6360091 | 0.86 | POLB (1.00) | POLBALDH1A1TP53BP1TP53NAMPT | |
| SCHEMBL27970190 | 0.86 | POLB (0.74) | POLBALDH1A1TP53BP1MRGPRX4TP53 | |
| SCHEMBL3512123 | 0.85 | POLB (0.72) | POLBALDH1A1TP53BP1TP53NAMPT | |
| SCHEMBL12201910 | 0.84 | POLB (0.58) | POLBALDH1A1TP53BP1 | |
| SCHEMBL19133512 | 0.84 | TP53BP1 (0.74) | POLBALDH1A1TP53BP1TP53NAMPT | |
| SCHEMBL19133527 | 0.84 | POLB (0.70) | POLBALDH1A1TP53BP1MRGPRX4TP53 | |
| SCHEMBL6359269 | 0.84 | POLB (0.84) | POLBALDH1A1TP53BP1MRGPRX4TP53 | |
| SCHEMBL16024734 | 0.84 | POLB (0.74) | POLBALDH1A1TP53BP1MRGPRX4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | POLB 3390/4885ALDH1A1 1154/4885TP53BP1 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.